GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panacos Pharmaceuticals Inc (GREY:PANC) » Definitions » EV-to-FCF

Panacos Pharmaceuticals (Panacos Pharmaceuticals) EV-to-FCF : 0.00 (As of Jun. 20, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Panacos Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Panacos Pharmaceuticals's Enterprise Value is $0.00 Mil. Panacos Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2008 was $-31.24 Mil. Therefore, Panacos Pharmaceuticals's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Panacos Pharmaceuticals's EV-to-FCF or its related term are showing as below:

PANC's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 6.29
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-20), Panacos Pharmaceuticals's stock price is $0.0001. Panacos Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2008 was $-0.660. Therefore, Panacos Pharmaceuticals's PE Ratio for today is At Loss.


Panacos Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Panacos Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacos Pharmaceuticals EV-to-FCF Chart

Panacos Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.68 -3.12 -11.66 -5.03 -0.33

Panacos Pharmaceuticals Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Panacos Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Panacos Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacos Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panacos Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Panacos Pharmaceuticals's EV-to-FCF falls into.



Panacos Pharmaceuticals EV-to-FCF Calculation

Panacos Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-31.243
=0.00

Panacos Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Panacos Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacos Pharmaceuticals  (GREY:PANC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Panacos Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-0.660
=At Loss

Panacos Pharmaceuticals's share price for today is $0.0001.
Panacos Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.660.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Panacos Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Panacos Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacos Pharmaceuticals (Panacos Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
134 Coolidge Avenue, Watertown, MA, USA, 02472
Panacos Pharmaceuticals Inc is a biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat HIV and other human viral diseases.

Panacos Pharmaceuticals (Panacos Pharmaceuticals) Headlines

No Headlines